The onset of type II diabetes (T2D) is slow and often asymptomatic until it has reached an advanced stage, by which point years of damage have likely already been done. Rather than wait for the onset of symptoms, T2D can be detected at earlier stages using metrics related to the disease’s most damaging characteristic, the impairment of glycemic control. Specifically, current clinical diagnostics rely on measurements of fasting plasma glucose, plasma glucose levels in response to an oral glucose tolerance test (OGTT), and, most recently, hemoglobin A1c, or HbA1c (and by “most recently” I mean over the past fifteen years). But while these tests are the most commonly used, are they all equally sufficient for detecting early stages of metabolic disease? Where does each succeed, and where does each fall short?
Would you like to read the full article?
This content is an exclusive benefit to
premium members
.
Premium members
get access to articles like this one, monthly “Ask Me Anything” podcast episodes, extensive show notes for every episode of
The Drive
, and more.
Become a Member
Already a subscriber?
Login here
.
If you are a member who is logged in and are receiving this message, please ensure the cookies are enabled on your browser.